Infusion Chemotherapy for Soft Tissue Sarcomas

  title={Infusion Chemotherapy for Soft Tissue Sarcomas},
  author={Robert S. Benjamin and Boh Seng Yap},
Adriamycin has formed the backbone of sarcoma chemotherapy since its introduction into clinical practice. The pioneering studies in this field by the late Dr. Jeffrey Gottlieb demonstrated modest but definite improvement in response rate, remission duration and survival when Adriamycin was combined with DIC and slight further improvement with the addition of cyclophosphamide [1–5]. Other drugs have been relatively ineffective, and the CyVADIC regimen, introduced in 1973, remains the standard of… 
The treatment of soft tissue sarcomas with focus on chemotherapy: a review.
  • H. Pinedo, J. Verweij
  • Medicine
    Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  • 1986
The Role of Chemotherapy in the Treatment of Adult Soft Tissue Sarcomas
There is the suggestion that responses may occur to ifosfamide in patients who progress on doxorubicin and the importance of treating all patients with soft tissue sarcomas in clinical trials is stressed.
Phase II new drug trials in soft tissue sarcomas
Considering this minimal advantage with the combination it is not surprising that several cooperative groups — ECOG and EORTC — have continued to use single-agent Adriamycin as their ‘standard’ of comparison, for first line treatment.
Chemotherapy in advanced soft tissue sarcomas
A complete remission can only be achieved in a limited number of patients, but there are indications that some of them may be cured, and the search for new active drugs for the treatment of soft tissue sarcomas continues.
Chemotherapy for metastatic soft tissue sarcomas.
  • W. Steward
  • Medicine
    Cancer treatment and research
  • 1997
This chapter summarizes the current knowledge of the activity of single-agent chemotherapy and of combination regimens, and reviews the potential value of high-dose and dose-intensive regimens.
Rhabdomyosarcoma of the oral soft tissues.
Freireich's laws in the treatment of sarcomas.
  • R. Benjamin
  • Medicine
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 1997
In his Karnofsky lecture of May 6, 1976, Dr. Emil J Freireich formalized seven of his multiple laws ( 1 ). Although this manuscript will not deal with law 7, the Regulators Creed, laws 1-6 are
Soft Tissue Sarcomas: New Developments in the Multidisciplinary Approach to Treatment
1. Pathology of Soft Tissue Sarcomas, 2. Diagnostic Imaging, 3. Principles of Surgical Treatment, and Thermochemotherapy for Soft T tissue Sarcoma of the Limbs.
Continuous-Infusion Adriamycin
Since an oncologist may not wish to stop treatment of an individual patient at an arbitrary level, a considerable investment of time and resources has been made in an effort to extend the use of adriamycin or develop analogs with diminished cardiotoxicity to accomplish the same aim.


Chemotherapy of sarcomas with a combination of adriamycin and dimethyl triazeno imidazole carboxamide
Combination therapy with adriamycin and DIC appears to be an effective and promising regimen in the treatment of metastatic sarcomas.
Cyclophosphamide, vincristine, adriamycin, and DTIC (CYVADIC) combination chemotherapy for the treatment of advanced sarcomas.
Pulmonary and soft tissue metastases were more responsive than bone and liver metastases and CYVADIC toxicity was predominantly limited to myelosuppression, vomiting, fever of unknown origin, and neuropathy.
Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion.
Cutting peak plasma levels of doxorubicin by continuous infusion reduces cardiotoxicity, and thus lessen cardiac toxicity, in patients treated by standard intravenous injection.